Another drug-production plant in India has been banned from imports to the U.S., this time that of Canada's Apotex, for all but one of the drugs it produces in Bangalore. The U.S. FDA issued the ban on the drugs, with the exception of its Riluzole (rilutek) for treating Lou Gehrig's disease, citing the plant's failure to meet good manufacturing practices. Apotex, which markets more than 300 generics, did not comment on the FDA action. The ban puts Apotex in the same league as Ranbaxy Laboratories and Wockhardt for drawing U.S. bans on their India plants. (Click here for more
)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?